Edition:
United States

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

3.56USD
4:00pm EDT
Change (% chg)

$0.15 (+4.40%)
Prev Close
$3.41
Open
$3.42
Day's High
$3.62
Day's Low
$3.42
Volume
71,749
Avg. Vol
130,145
52-wk High
$6.73
52-wk Low
$1.29

Select another date:

Thu, Mar 29 2018

BRIEF-Galectin Therapeutics Provides Business Update

* GALECTIN THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Galectin Therapeutics Says $10 Mln Credit Line From Richard Uihlein Sufficient To Cover Expected Expenditures Into 2019

* GALECTIN THERAPEUTICS ANNOUNCES $10 MILLION CREDIT LINE FROM RICHARD E. UIHLEIN SUFFICIENT TO COVER EXPECTED EXPENDITURES INTO 2019

Galectin slumps after NASH drug misses main goal of mid-stage trial

Galectin Therapeutics Inc said its drug for the complex progressive fatty liver disease NASH led to some clinically meaningful results in patients with cirrhosis, but failed to achieve the main goal of a mid-stage trial, sending its shares plunging 48 percent on Tuesday.

UPDATE 1-Galectin slumps after NASH drug misses main goal of mid-stage trial

Dec 5 Galectin Therapeutics Inc said its drug for the complex progressive fatty liver disease NASH led to some clinically meaningful results in patients with cirrhosis, but failed to achieve the main goal of a mid-stage trial, sending its shares plunging 48 percent on Tuesday.

BRIEF-Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results

* Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results in treatment of advanced melanoma from a phase 1b clinical trial Source text for Eikon: Further company coverage:

BRIEF-Galectin Therapeutics posts qtrly loss per share $0.13‍​

* Galectin Therapeutics Inc - ‍Top line results of NASH-CX phase 2B clinical trial expected to be announced in early December 2017​

Select another date: